Haemophilus Infections: all 176 studies
Page 2 of 2. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.
- Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesCompletedNCT05457946Phase 2/3
- Safety and Reactogenicity Trial of Vaccine for the Prevention of Infections Caused by Haemophilus Influenzae Type bCompletedNCT05401305Phase 1
- Variations in the Composition of Respiratory MicrobiotaCompletedNCT04747184
- Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaCompletedNCT04177485Not applicable
- Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsStatus unknownNCT04073459Phase 2
- A Phase IV Study to Assess the Safety of EupentaTM InjStatus unknownNCT04056728Phase 4
- The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 WeeksCompletedNCT03931239Not applicable
- Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable
- Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanStatus unknownNCT03341195Not applicable
- A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsCompletedNCT03208101Phase 1
- Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian InfantsWithdrawnNCT03128489Phase 3
- Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-driedStatus unknownNCT02560272Phase 3
- Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After BirthCompletedNCT02428491Phase 3
- DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed InfantsCompletedNCT02094833Phase 3
- Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa VaccinationCompletedNCT01983540Phase 3
- A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and UnijectCompletedNCT01917357Phase 3
- Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaCompletedNCT01878435Not applicable
- Neisseria Meningitidis Burden of Disease StudyCompletedNCT01730391
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in ToddlersCompletedNCT01485406Phase 1
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio VaccineCompletedNCT01457560Phase 3
- Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination CourseCompletedNCT01457547Phase 4
- Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered SeparatelyCompletedNCT01457508Phase 3
- Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered ConcomitantlyCompletedNCT01457495Phase 2
- Safety of Haemophilus Influenza Type b Vaccine When Administered to Korean ChildrenCompletedNCT01404962Phase 4
- A Study to Identify and Characterise Bacteria Causing Chronic Cough Among Children in United KingdomTerminatedNCT01292213
- Immunogenicity and Safety of a Booster Dose of Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 365-569 Days Old Healthy InfantsCompletedNCT01226953Phase 3
- Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.CompletedNCT01214889Phase 3
- Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy ChildrenCompletedNCT01125527Phase 3
- A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy InfantsCompletedNCT01062477Phase 3
- Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™CompletedNCT01061541Phase 2
- Study in Infants (6-12 Months) Comparing Two Doses of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Vaccine Versus a Tetanus Toxoid-Conjugated Vaccine Available for the Prevention of Haemophilus Influenzae Type b Infections in ChinaCompletedNCT01044316Phase 3
- Study in Toddlers (12-18 Months) Comparing a Booster Dose of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b Infections in ChinaCompletedNCT01025544Phase 3
- Microbiota of the Respiratory Flora in Children With Cystic Fibrosis During the First Year of LifeWithdrawnNCT00977158
- Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable DiseaseStatus unknownNCT00932269
- Nontypeable H. Influenzae in Healthy AdultsCompletedNCT00905385Phase 1/2
- Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination VaccineStatus unknownNCT00877357Phase 4
- Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseCompletedNCT00855855
- Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate VaccineTerminatedNCT00849069Phase 1
- Host-pathogen Interaction in Otitis MediaStatus unknownNCT00847756
- Safety and Immunogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type bCompletedNCT00808392Phase 3
- Database Surveillance Safety Study of PENTACEL® VaccineCompletedNCT00804284
- Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type bCompletedNCT00734565Phase 1
- Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineCompletedNCT00674908Phase 4
- Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended VaccineCompletedNCT00662870Phase 3
- A Study to Gather Safety Data Following Administration of a Hib-containing Booster Vaccine in Children Aged Two to Five YearsCompletedNCT00625118
- Safety and Immunogenicity Study of a Liquid Pentavalent Combination VaccineCompletedNCT00617812Phase 4
- Middle Meatal Bacteriology During Acute Respiratory Infection in ChildrenStatus unknownNCT00545961Phase 4
- Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 MonthsCompletedNCT00453570Phase 3
- Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of AgeCompletedNCT00379977Phase 3
- Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of AgeCompletedNCT00376779Phase 2
- Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®CompletedNCT00362427Phase 2
- Study to Compare Booster Vaccination With Pediacel® to Infanrix® Hexa When Both Are Co-Administered With Prevenar®CompletedNCT00355654Phase 3
- Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and ToddlersCompletedNCT00343421Phase 3
- Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/HibCompletedNCT00332566Phase 3
- Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC VaccineCompletedNCT00327184Phase 3
- Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old SubjectsCompletedNCT00323050Phase 3
- Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.CompletedNCT00317187Phase 3
- A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.CompletedNCT00317174Phase 2
- Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.CompletedNCT00317161Phase 3
- Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.CompletedNCT00317135Phase 3
- Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at BirthCompletedNCT00317122Phase 3
- Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.TerminatedNCT00316680Phase 3
- Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination SchedulesCompletedNCT00316147Phase 3
- Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488CompletedNCT00307567Phase 2
- Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy InfantsCompletedNCT00290303Phase 3
- Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in InfantsCompletedNCT00287092Phase 3
- Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197CompletedNCT00263653Phase 3
- Immunogenicity and Safety of Pentaxim™ in an Indian PopulationCompletedNCT00259337Phase 3
- Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C VaccineCompletedNCT00258700Phase 3
- Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in ThailandCompletedNCT00255021Phase 4
- Immunogenicity and Safety of Pentaxim in South African InfantsCompletedNCT00254969Phase 3
- Assessment of the Immunogenicity and Safety of PENTAXIM™ in PhilippinesCompletedNCT00254917Phase 4
- The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib VaccineCompletedNCT00197782Phase 4
- Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in InfantsCompletedNCT00197275Phase 3
- Vaccination of Children Following Allogeneic Stem Cell TransplantationCompletedNCT00169728Phase 3
- Study to Eliminate Hib Carriage in Rural Alaska Native VillagesCompletedNCT00153556Phase 4